• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
DFFN

DFFN

Diffusion Pharmaceuticals Inc.

NASDAQHealthcareBiotechnologyUS

USD4.40

+0.41 (+10.28%)

Company Profile

CEO

Robert J. Cobuzzi Jr.,

IPO Date

2008-05-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.23

Prev. Close

$3.99

Day Low

$4.17

Day High

$5.19

52W Low

$4.14

52W High

$14.37

Market Cap

$0.01B

Volume

0.35M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

34.0%

Avg Negative

2.1%

Avg Neutral

63.9%

News Feed

DFFN Stock: Over 7% Increase Pre-Market Explanation

Pulse2·8/30/2021·↑ positive

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division

GlobeNewsWire·8/30/2021·↑ positive

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

GlobeNewsWire
·8/11/2021
·↑ positive

Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation

Benzinga·6/30/2021·↑ positive

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

GlobeNewsWire·6/30/2021·↑ positive

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum

GlobeNewsWire·6/21/2021·↓ negative

Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting

GlobeNewsWire·6/18/2021·↓ negative

Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June

PennyStocks·6/9/2021·↑ positive

Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

GlobeNewsWire·5/10/2021·↑ positive

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

GlobeNewsWire·3/25/2021·↑ positive